Medical Care
Global Neurodegenerative Diseases Therapeutics Market Research Report 2025
- Apr 07, 25
- ID: 167775
- Pages: 78
- Figures: 71
- Views: 33
The global market for Neurodegenerative Diseases Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Therapeutics.
The Neurodegenerative Diseases Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Segment by Type
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Diseases Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Diseases Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Diseases Therapeutics.
The Neurodegenerative Diseases Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neurodegenerative Diseases Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Diseases Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AB Science SA
AbbVie Inc.
Acadia Pharmaceuticals Inc.
Biogen Inc.
F. Hoffmann La Roche Ltd.
H Lundbeck AS
Mitsubishi Chemical Holdings Corp.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd
Segment by Type
Multiple Sclerosis Therapeutics
Alzheimer's Disease Therapeutics
Parkinson's Disease Therapeutics
Parkinson's Disease Therapeutics
Others
Segment by Application
Child
Aldult
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neurodegenerative Diseases Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Multiple Sclerosis Therapeutics
1.2.3 Alzheimer's Disease Therapeutics
1.2.4 Parkinson's Disease Therapeutics
1.2.5 Parkinson's Disease Therapeutics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Child
1.3.3 Aldult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2020-2031)
2.2 Global Neurodegenerative Diseases Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurodegenerative Diseases Therapeutics Revenue
3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2024
3.5 Global Key Players of Neurodegenerative Diseases Therapeutics Head office and Area Served
3.6 Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application
3.7 Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
6.2 North America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
9.2 Latin America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AB Science SA
11.1.1 AB Science SA Company Details
11.1.2 AB Science SA Business Overview
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.1.5 AB Science SA Recent Development
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Details
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.2.5 AbbVie Inc. Recent Development
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Details
11.3.2 Acadia Pharmaceuticals Inc. Business Overview
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.3.5 Acadia Pharmaceuticals Inc. Recent Development
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Details
11.4.2 Biogen Inc. Business Overview
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.4.5 Biogen Inc. Recent Development
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Details
11.5.2 F. Hoffmann La Roche Ltd. Business Overview
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.5.5 F. Hoffmann La Roche Ltd. Recent Development
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Details
11.6.2 H Lundbeck AS Business Overview
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.6.5 H Lundbeck AS Recent Development
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Details
11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Details
11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Multiple Sclerosis Therapeutics
1.2.3 Alzheimer's Disease Therapeutics
1.2.4 Parkinson's Disease Therapeutics
1.2.5 Parkinson's Disease Therapeutics
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Child
1.3.3 Aldult
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Therapeutics Market Perspective (2020-2031)
2.2 Global Neurodegenerative Diseases Therapeutics Growth Trends by Region
2.2.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neurodegenerative Diseases Therapeutics Historic Market Size by Region (2020-2025)
2.2.3 Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031)
2.3 Neurodegenerative Diseases Therapeutics Market Dynamics
2.3.1 Neurodegenerative Diseases Therapeutics Industry Trends
2.3.2 Neurodegenerative Diseases Therapeutics Market Drivers
2.3.3 Neurodegenerative Diseases Therapeutics Market Challenges
2.3.4 Neurodegenerative Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Therapeutics Players by Revenue (2020-2025)
3.1.2 Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Players (2020-2025)
3.2 Global Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neurodegenerative Diseases Therapeutics Revenue
3.4 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Therapeutics Revenue in 2024
3.5 Global Key Players of Neurodegenerative Diseases Therapeutics Head office and Area Served
3.6 Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application
3.7 Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurodegenerative Diseases Therapeutics Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Type (2020-2025)
4.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031)
5 Neurodegenerative Diseases Therapeutics Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Therapeutics Historic Market Size by Application (2020-2025)
5.2 Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
6.2 North America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
6.4 North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
7.2 Europe Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
7.4 Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025)
8.4 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
9.2 Latin America Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
9.4 Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size (2020-2031)
10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025)
10.4 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AB Science SA
11.1.1 AB Science SA Company Details
11.1.2 AB Science SA Business Overview
11.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Introduction
11.1.4 AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.1.5 AB Science SA Recent Development
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Details
11.2.2 AbbVie Inc. Business Overview
11.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Introduction
11.2.4 AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.2.5 AbbVie Inc. Recent Development
11.3 Acadia Pharmaceuticals Inc.
11.3.1 Acadia Pharmaceuticals Inc. Company Details
11.3.2 Acadia Pharmaceuticals Inc. Business Overview
11.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Introduction
11.3.4 Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.3.5 Acadia Pharmaceuticals Inc. Recent Development
11.4 Biogen Inc.
11.4.1 Biogen Inc. Company Details
11.4.2 Biogen Inc. Business Overview
11.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Introduction
11.4.4 Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.4.5 Biogen Inc. Recent Development
11.5 F. Hoffmann La Roche Ltd.
11.5.1 F. Hoffmann La Roche Ltd. Company Details
11.5.2 F. Hoffmann La Roche Ltd. Business Overview
11.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Introduction
11.5.4 F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.5.5 F. Hoffmann La Roche Ltd. Recent Development
11.6 H Lundbeck AS
11.6.1 H Lundbeck AS Company Details
11.6.2 H Lundbeck AS Business Overview
11.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Introduction
11.6.4 H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.6.5 H Lundbeck AS Recent Development
11.7 Mitsubishi Chemical Holdings Corp.
11.7.1 Mitsubishi Chemical Holdings Corp. Company Details
11.7.2 Mitsubishi Chemical Holdings Corp. Business Overview
11.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Introduction
11.7.4 Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.7.5 Mitsubishi Chemical Holdings Corp. Recent Development
11.8 Novartis AG
11.8.1 Novartis AG Company Details
11.8.2 Novartis AG Business Overview
11.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Introduction
11.8.4 Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.8.5 Novartis AG Recent Development
11.9 Sanofi
11.9.1 Sanofi Company Details
11.9.2 Sanofi Business Overview
11.9.3 Sanofi Neurodegenerative Diseases Therapeutics Introduction
11.9.4 Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.9.5 Sanofi Recent Development
11.10 Teva Pharmaceutical Industries Ltd
11.10.1 Teva Pharmaceutical Industries Ltd Company Details
11.10.2 Teva Pharmaceutical Industries Ltd Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Introduction
11.10.4 Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025)
11.10.5 Teva Pharmaceutical Industries Ltd Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Multiple Sclerosis Therapeutics
Table 3. Key Players of Alzheimer's Disease Therapeutics
Table 4. Key Players of Parkinson's Disease Therapeutics
Table 5. Key Players of Parkinson's Disease Therapeutics
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2025)
Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2026-2031)
Table 13. Neurodegenerative Diseases Therapeutics Market Trends
Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)
Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Neurodegenerative Diseases Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application
Table 24. Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. AB Science SA Company Details
Table 50. AB Science SA Business Overview
Table 51. AB Science SA Neurodegenerative Diseases Therapeutics Product
Table 52. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 53. AB Science SA Recent Development
Table 54. AbbVie Inc. Company Details
Table 55. AbbVie Inc. Business Overview
Table 56. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
Table 57. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 58. AbbVie Inc. Recent Development
Table 59. Acadia Pharmaceuticals Inc. Company Details
Table 60. Acadia Pharmaceuticals Inc. Business Overview
Table 61. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
Table 62. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 63. Acadia Pharmaceuticals Inc. Recent Development
Table 64. Biogen Inc. Company Details
Table 65. Biogen Inc. Business Overview
Table 66. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
Table 67. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Biogen Inc. Recent Development
Table 69. F. Hoffmann La Roche Ltd. Company Details
Table 70. F. Hoffmann La Roche Ltd. Business Overview
Table 71. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
Table 72. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 73. F. Hoffmann La Roche Ltd. Recent Development
Table 74. H Lundbeck AS Company Details
Table 75. H Lundbeck AS Business Overview
Table 76. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
Table 77. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 78. H Lundbeck AS Recent Development
Table 79. Mitsubishi Chemical Holdings Corp. Company Details
Table 80. Mitsubishi Chemical Holdings Corp. Business Overview
Table 81. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
Table 82. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Mitsubishi Chemical Holdings Corp. Recent Development
Table 84. Novartis AG Company Details
Table 85. Novartis AG Business Overview
Table 86. Novartis AG Neurodegenerative Diseases Therapeutics Product
Table 87. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Novartis AG Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Neurodegenerative Diseases Therapeutics Product
Table 92. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Teva Pharmaceutical Industries Ltd Company Details
Table 95. Teva Pharmaceutical Industries Ltd Business Overview
Table 96. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
Table 97. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Teva Pharmaceutical Industries Ltd Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Neurodegenerative Diseases Therapeutics Picture
Figure 2. Global Neurodegenerative Diseases Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Multiple Sclerosis Therapeutics Features
Figure 5. Alzheimer's Disease Therapeutics Features
Figure 6. Parkinson's Disease Therapeutics Features
Figure 7. Parkinson's Disease Therapeutics Features
Figure 8. Others Features
Figure 9. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Child Case Studies
Figure 12. Aldult Case Studies
Figure 13. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2024
Figure 18. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2024
Figure 20. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2031)
Figure 34. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 50. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 51. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 52. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 53. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 54. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 55. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 56. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 57. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 58. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Multiple Sclerosis Therapeutics
Table 3. Key Players of Alzheimer's Disease Therapeutics
Table 4. Key Players of Parkinson's Disease Therapeutics
Table 5. Key Players of Parkinson's Disease Therapeutics
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Neurodegenerative Diseases Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2025)
Table 11. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Therapeutics Market Share by Region (2026-2031)
Table 13. Neurodegenerative Diseases Therapeutics Market Trends
Table 14. Neurodegenerative Diseases Therapeutics Market Drivers
Table 15. Neurodegenerative Diseases Therapeutics Market Challenges
Table 16. Neurodegenerative Diseases Therapeutics Market Restraints
Table 17. Global Neurodegenerative Diseases Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Therapeutics Market Share by Players (2020-2025)
Table 19. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)
Table 20. Ranking of Global Top Neurodegenerative Diseases Therapeutics Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Therapeutics Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Neurodegenerative Diseases Therapeutics, Headquarters and Area Served
Table 23. Global Key Players of Neurodegenerative Diseases Therapeutics, Product and Application
Table 24. Global Key Players of Neurodegenerative Diseases Therapeutics, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Therapeutics Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2020-2025)
Table 28. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Type (2026-2031)
Table 30. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2020-2025)
Table 32. Global Neurodegenerative Diseases Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Neurodegenerative Diseases Therapeutics Revenue Market Share by Application (2026-2031)
Table 34. North America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country (2026-2031) & (US$ Million)
Table 49. AB Science SA Company Details
Table 50. AB Science SA Business Overview
Table 51. AB Science SA Neurodegenerative Diseases Therapeutics Product
Table 52. AB Science SA Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 53. AB Science SA Recent Development
Table 54. AbbVie Inc. Company Details
Table 55. AbbVie Inc. Business Overview
Table 56. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product
Table 57. AbbVie Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 58. AbbVie Inc. Recent Development
Table 59. Acadia Pharmaceuticals Inc. Company Details
Table 60. Acadia Pharmaceuticals Inc. Business Overview
Table 61. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product
Table 62. Acadia Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 63. Acadia Pharmaceuticals Inc. Recent Development
Table 64. Biogen Inc. Company Details
Table 65. Biogen Inc. Business Overview
Table 66. Biogen Inc. Neurodegenerative Diseases Therapeutics Product
Table 67. Biogen Inc. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 68. Biogen Inc. Recent Development
Table 69. F. Hoffmann La Roche Ltd. Company Details
Table 70. F. Hoffmann La Roche Ltd. Business Overview
Table 71. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product
Table 72. F. Hoffmann La Roche Ltd. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 73. F. Hoffmann La Roche Ltd. Recent Development
Table 74. H Lundbeck AS Company Details
Table 75. H Lundbeck AS Business Overview
Table 76. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product
Table 77. H Lundbeck AS Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 78. H Lundbeck AS Recent Development
Table 79. Mitsubishi Chemical Holdings Corp. Company Details
Table 80. Mitsubishi Chemical Holdings Corp. Business Overview
Table 81. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product
Table 82. Mitsubishi Chemical Holdings Corp. Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 83. Mitsubishi Chemical Holdings Corp. Recent Development
Table 84. Novartis AG Company Details
Table 85. Novartis AG Business Overview
Table 86. Novartis AG Neurodegenerative Diseases Therapeutics Product
Table 87. Novartis AG Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 88. Novartis AG Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Neurodegenerative Diseases Therapeutics Product
Table 92. Sanofi Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Teva Pharmaceutical Industries Ltd Company Details
Table 95. Teva Pharmaceutical Industries Ltd Business Overview
Table 96. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product
Table 97. Teva Pharmaceutical Industries Ltd Revenue in Neurodegenerative Diseases Therapeutics Business (2020-2025) & (US$ Million)
Table 98. Teva Pharmaceutical Industries Ltd Recent Development
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
Table 102. Authors List of This Report
List of Figures
Figure 1. Neurodegenerative Diseases Therapeutics Picture
Figure 2. Global Neurodegenerative Diseases Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Neurodegenerative Diseases Therapeutics Market Share by Type: 2024 VS 2031
Figure 4. Multiple Sclerosis Therapeutics Features
Figure 5. Alzheimer's Disease Therapeutics Features
Figure 6. Parkinson's Disease Therapeutics Features
Figure 7. Parkinson's Disease Therapeutics Features
Figure 8. Others Features
Figure 9. Global Neurodegenerative Diseases Therapeutics Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Neurodegenerative Diseases Therapeutics Market Share by Application: 2024 VS 2031
Figure 11. Child Case Studies
Figure 12. Aldult Case Studies
Figure 13. Neurodegenerative Diseases Therapeutics Report Years Considered
Figure 14. Global Neurodegenerative Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Neurodegenerative Diseases Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Neurodegenerative Diseases Therapeutics Market Share by Region: 2024 VS 2031
Figure 17. Global Neurodegenerative Diseases Therapeutics Market Share by Players in 2024
Figure 18. Global Top Neurodegenerative Diseases Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurodegenerative Diseases Therapeutics as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Therapeutics Revenue in 2024
Figure 20. North America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 22. United States Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 26. Germany Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Neurodegenerative Diseases Therapeutics Market Share by Region (2020-2031)
Figure 34. China Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 42. Mexico Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Neurodegenerative Diseases Therapeutics Market Share by Country (2020-2031)
Figure 46. Turkey Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Neurodegenerative Diseases Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. AB Science SA Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 50. AbbVie Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 51. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 52. Biogen Inc. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 53. F. Hoffmann La Roche Ltd. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 54. H Lundbeck AS Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 55. Mitsubishi Chemical Holdings Corp. Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 56. Novartis AG Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 57. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 58. Teva Pharmaceutical Industries Ltd Revenue Growth Rate in Neurodegenerative Diseases Therapeutics Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Oral Antianginal Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Polyester BCF Yarns Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Global Glass Mat Reinforced Thermoplastics (GMT) for Automotive Market Outlook, In‑Depth Analysis & Forecast to 2031
Oct 21, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232